vitamin-b-12 and Bone-Neoplasms

Topics: Bone Neoplasms; Calcium Isotopes; Child, Preschool; Contrast Media; Humans; Intestinal Absorption; Iodine Radioisotopes; Iodipamide; Iron; Neoplasm Metastasis; Potassium Isotopes; Radiometry; Strontium Isotopes; Vitamin B 12

High serum homocysteine (HCY) and indirectly deficiency of folate and/or vitamin B(12) stimulate bone resorption and adversely affect collagen cross-linking. The aim of this study was the evaluation of serum levels of HCY, folate and vitamin B(12) in patients with Paget's disease of bone (PDB) and the effect of zoledronic acid (ZOL) on their serum levels. Nine consecutive patients with polyostotic PDB (median age 66 years) received a single 5-mg ZOL infusion. Blood samples for HCY, folate, vitamin B(12), 25-hydroxyvitamin D (25-OH-D), total serum alkaline phosphatase (TSAP), bone-specific serum alkaline phosphatase (BSAP) and C-terminal cross-linking telopeptide of type I collagen (CTX) were obtained at baseline and 3, 6 and 12 months after ZOL infusion. Twelve age-, gender- and BMI-matched healthy individuals were recruited for the control group at baseline assessment. Patients with PDB had significantly higher serum HCY (p = 0.028), folate (p < 0.001) and bone markers [TSAP (p < 0.001), BSAP (p < 0.001) and CTX (p < 0.001)] compared with the control group at baseline. In the pagetic group, serum HCY significantly decreased 3 months after ZOL infusion and remained essentially unchanged up to the end of the study (p = 0.005). Serum vitamin B(12) and folate remained unaffected throughout the study. Our data suggest that serum HCY levels are increased in patients with PDB. A single ZOL infusion results in a decrease in HCY levels that might represent another mechanism for the reduction of the activity of PDB achieved by ZOL.

Topics: 25-Hydroxyvitamin D 2; Aged; Alkaline Phosphatase; Biomarkers; Body Mass Index; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Calcifediol; Cohort Studies; Collagen Type I; Diphosphonates; Female; Folic Acid; Homocysteine; Humans; Imidazoles; Isoenzymes; Male; Paget Disease, Extramammary; Peptides; Pilot Projects; Time Factors; Vitamin B 12; Zoledronic Acid

Bronchioloalveolar carcinoma (BAC) and adenocarcinoma mixed subtype with bronchioloalveolar features (ADC-WBF) represent a unique anatomo-clinical entity accounting for some 20% of non-small cell lung cancers (NSCLC). These tumors seem less sensitive to chemotherapy than other NSCLC. We report two cases of advanced ADC-WBF treated with second-line and fourth-line pemetrexed. Major and durable radiological response associated with clinical and functional improvement was achieved in both patients, without important drug toxicity. After treatment arrest, the two patients experienced progressive disease but responded to retreatment with pemetrexed. Recent data suggest that paclitaxel-based chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors could be an acceptable therapeutic strategy in unresectable CBA and ADC-WBF. The cases reported here and preclinical findings suggest a therapeutic efficacy of pemetrexed in these tumors. Prospective studies are required to evaluate this hypothesis.

Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Cough; Disease Progression; Dyspnea; Folic Acid; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Pemetrexed; Remission Induction; Renal Insufficiency; Smoking; Tomography, X-Ray Computed; Vitamin B 12

The role of folate metabolism in cancer development is a topic of much current interest, with maintenance of adequate folate status tending to show a protective effect. Aberrant methylation, primarily hypermethylation of certain genes including tumor suppressors, has been implicated in prostate cancer development. Folate, vitamin B12 and homocysteine are essential for methyl group metabolism and thus also for DNA methylation. We related plasma levels of these factors to prostate cancer risk in a prospective study of 254 case subjects and 514 matched control subjects. Increasing plasma levels of folate and vitamin B12 were statistically significantly associated with increased prostate cancer risk, with an odds ratio of 1.60 (95% CI = 1.03-2.49; p(trend) = 0.02) for folate and 2.63 (95% CI = 1.61-4.29; p(trend) < 0.001) for vitamin B12 for highest vs. lowest quartile. Increasing plasma homocysteine levels were associated with a reduced risk of borderline significance (OR = 0.67; 95% CI = 0.43-1.04; p(trend) = 0.08). After adjustment for the other 2 plasma variables, body mass index and smoking, a statistically significant increased risk remained only for vitamin B12 (OR = 2.96; 95% CI = 1.58-5.55; p(trend) = 0.001). Adjusted OR for folate and homocysteine were 1.30 (95% CI = 0.74-2.24; p(trend) = 0.17) and 0.91 (95% CI = 0.51-1.58; p(trend) = 0.60), respectively. Our results suggest that factors contributing to folate status are not protective against prostate cancer. On the contrary, vitamin B12, associated with an up to 3-fold increase in risk, and possibly also folate, may even stimulate prostate cancer development. These findings are novel and should be explored further in future studies.

Topics: Adult; Aged; Bone Neoplasms; Case-Control Studies; Folic Acid; Homocysteine; Humans; Lymphatic Metastasis; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Risk Factors; Sweden; Vitamin B 12

Topics: Aged; Alkaline Phosphatase; Bone Neoplasms; Eosinophilia; Humans; Male; Muramidase; Neoplasm Metastasis; Pericardium; Pleura; Pleural Effusion; Pleural Neoplasms; Ribs; Vitamin B 12

Topics: Bone Neoplasms; Female; Humans; Infant; Male; Neoplasm Metastasis; Neuroblastoma; Vitamin B 12

Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Bone Neoplasms; Child, Preschool; Female; Fetus; Humans; Infant; Infant, Newborn; Infant, Premature; Neoplasm Metastasis; Neuroblastoma; Pregnancy; Radiography, Abdominal; Teratoma; Vitamin B 12

Topics: Bone Neoplasms; Corrinoids; Cyclophosphamide; Humans; Infant; Lymphatic Metastasis; Neuroblastoma; Prognosis; Radiography; Vitamin B 12